eprintid: 10153332
rev_number: 8
eprint_status: archive
userid: 699
dir: disk0/10/15/33/32
datestamp: 2022-08-05 10:40:47
lastmod: 2022-08-05 10:40:47
status_changed: 2022-08-05 10:40:47
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Jensen, Nele
creators_name: Barry, Andrew
creators_name: Kelly, Ann H
title: More-than-national and less-than-global: The biochemical infrastructure of vaccine manufacturing
ispublished: inpress
divisions: C03
divisions: F26
divisions: B03
divisions: UCL
keywords: Vaccine R&D, COVID-19, biochemical engineering, infrastructure, equity
note: This work is licensed under a Creative Commons Attribution 4.0 International License. The images
or other third-party material in this article are included in the Creative Commons license,
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
abstract: The recent efforts to mount an R&D response to public health emergencies of international concern have led to the formation of what we term a biochemical infrastructure of vaccine development and production. In principle, this infrastructure is expected not only to curtail existing pandemics but also anticipate and contain yet-to-emerge future threats. Critically, by nature of its geographical distribution and technical modularity, that infrastructure promises both to accelerate and expand access to essential medical tools, and in so doing, redress global health inequities. In practice, however, the biochemical infrastructure of vaccines remains highly uneven, fragmented and unjust. Moving beyond calls for ‘global health solidarity’, this paper examines the key actors, normative techniques and socio-technical assemblages, from viral platform technologies to intellectual property waivers and from accelerated regulatory pathways to advance market commitments, that serve to link ‘just-in-case’ and ‘just-in-time’ modalities of global health R&D. We argue that the biomedical infrastructure of vaccine development and production emerging in the wake of the COVID-19 pandemic is unfolding across an innovation ecosystem that is more-than-national and yet less-than global: a reconfiguration that may offer possibilities for a new, radically-overhauled, model of vaccine equity.
date: 2022-08-01
date_type: published
publisher: Informa UK Limited
official_url: https://doi.org/10.1080/03085147.2022.2087899
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1968546
doi: 10.1080/03085147.2022.2087899
lyricists_name: Barry, Andrew
lyricists_id: AMBAR34
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Economy and Society
citation:        Jensen, Nele;    Barry, Andrew;    Kelly, Ann H;      (2022)    More-than-national and less-than-global: The biochemical infrastructure of vaccine manufacturing.                   Economy and Society        10.1080/03085147.2022.2087899 <https://doi.org/10.1080/03085147.2022.2087899>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10153332/1/More%20than%20national%20and%20less%20than%20global%20The%20biochemical%20infrastructure%20of%20vaccine%20manufacturing.pdf